Schrödinger Reports Third Quarter 2026 Financial Results

What happened

Schrödinger reported results for the quarter ended September 30, 2026. Annual contract value (ACV), a measure of recurring customer commitments, rose 17% to $44.7 million; software revenue increased 6% to $38.2 million, including hosted software revenue up 49% to $17.2 million. The company said it raised its full-year ACV and drug discovery revenue outlook.

Confirmed

Global impact / market context

Growth in recurring customer commitments and hosted software revenue suggests stronger demand for Schrödinger’s software, while drug discovery work provides another revenue stream. If the two businesses reinforce one another as management says, project work could help win software commitments, supporting future revenue; the supplied text does not quantify that effect.

Analyst inference

The reported figures show faster growth in hosted software revenue than in total software revenue, while ACV also increased. That mix points to hosted offerings as a current growth contributor, but the supplied excerpt gives no full-year guidance figures, profitability data, cash position, or market reaction for comparison.

Analyst inference

What to watch

1. Look for the company’s full-year ACV and drug discovery revenue outlook figures; the excerpt confirms an increase in guidance but does not state the revised targets. Confirmed
2. Track whether hosted software revenue continues to grow faster than total software revenue, since sustained gains could increase recurring software income and customer commitments. Analyst inference
3. Watch whether drug discovery programs lead partners to expand software commitments, as management describes this feedback loop but the excerpt does not establish its financial size. Analyst inference

Evidence

• Original source link unavailable